ArticleDiagnostics (Basel, Switzerland)2021

FDG-PET/CT for Response Monitoring in Metastatic Breast Cancer: The Feasibility and Benefits of Applying PERCIST.

Marianne Vogsen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.